secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silk Road Medical Inc (—)
CIK:        0001397702
Form:       8-K
Filed at:   2024-09-17T23:59:59+00:00
Accession:  0001140361-24-041264
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.03, 2.04, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific closes acquisition of Silk Road Medical for $27.50 per share
------------------------------------------------------------------------------

- Merger closed on September 17, 2024; shareholders received $27.50 per share in cash.
- Silk Road became a wholly owned subsidiary of Boston Scientific; stock delisted from Nasdaq.
- Previous board and officers (including CEO Charles McKhann) replaced by Boston Scientific appointees.
- Existing loan agreement with Oxford Finance repaid in full with 1% prepayment fee; success fee paid to Stifel Bank.
- Company will file Form 15 to terminate SEC reporting obligations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1397702/000114036124041264/0001140361-24-041264-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1397702/000114036124041264/ef20035938_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-041264

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer